Cangene Wins Auction for Inspiration's Hemophilia Drug

February 6, 2013

Inspiration Biopharmaceuticals Inc. reached a deal to sell its second development-stage hemophilia drug at auction Tuesday to Cangene Corp. for $5.9 million in cash upfront plus royalties and milestone payments worth $50 million.

Cangene expects the sale, which still requires bankruptcy-court approval, to close by Feb. 15, it said in a news release.

Click here for the article.

Share This Story